IP Library › Granted Patent US 12,344,597
Granted Patent B2
US 12,344,597 · App. 16/972,878 · Granted Jul 1, 2025

Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis

Inventors: Martin Bolli (Allschwil, CH); Christine Brotschi (Allschwil, CH); Cyrille Lescop (Allschwil, CH); Jodi T. Williams (Allschwil, CH)
Assignee: IDORSIA PHARMACEUTICALS LTD
C07D401/12A61P9/14C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,597
App. No.
16/972,878
Granted
Jul 1, 2025
Kind
B2
Abstract

The present invention relates to pyridinyl derivatives of Formula (I) Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Ar 1 , L, W, Z, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.

Claims (226)

1. A compound of Formula (I),

wherein

W represents N, and Z represents CH; or

Z represents N, and W represents CH;

R 1 is hydrogen or fluoro;

R 2 is hydrogen, halogen, methyl, ethyl, methoxy or ethoxy;

R 3 is C 1-3 -fluoroalkoxy;

Ar 1 represents phenyl, wherein said group Ar 1 is substituted with R 4 and R 5 , wherein

R 4 is n-propyl, isopropyl, C 3-6 -cycloalkyl optionally containing a ring oxygen atom, or cyclopent-1-en-1-yl; and

R 5 represents one substituent independently selected from hydrogen, fluoro, methyl or methoxy;

m and n represent the integer 1; and

the group -L—R 6 represents

-L 1 -COOH; wherein

-L 1 - represents

-C 1-6 -alkylene-, —CO—C 1-6 -alkylene-, —SO 2 -C 1-6 -alkylene-, —CO—O-C 1-6 -alkylene-, —CO—NH-C 1-6 -alkylene-, or —SO 2 —NH-C 1-6 -alkylene-;

—CO-C 1-6 -alkylene-; wherein said C 1-6 -alkylene is mono-substituted with hydroxy;

-C 0-4 -alkylene-C 3-8 -cycloalkylene-C 0-4 -alkylene-, —CO-C 0-4 -alkylene-C 3-8 -cycloalkylene-C 0-4 -alkylene-, —SO 2 -C 0-4 -alkylene-C 3-8 -cycloalkylene-C 0-4 -alkylene-, or —CO-O-C 0-4 -alkylene-C 3-8 -cycloalkylene-C 0-4 -alkylene-;

—CO-C 0-4 -alkylene-Cy 1 -C 0-4 -alkylene-; wherein Cy 1 independently represents a C 3-6 -heterocycloalkylene containing one ring oxygen atom;

—CO-C 1-4 -alkylene-X 12 -C 1-4 -alkylene-; wherein X 12 independently represents a nitrogen atom which is unsubstituted, or mono-substituted with C 1-4 -alkyl;

—CO-C 2-6 -alkenylene- or —SO 2 -C 2-6 -alkenylene-; or

—CO-C 2-6 -fluoroalkylene-;

-L 2 -hydroxy; wherein -L 2 - represents

-C 2-6 -alkylene-, wherein the C 2-6 -alkylene is unsubstituted, or mono-substituted with hydroxy; or

—CO-C 1-4 -alkylene-X 22 -C 2-4 -alkylene-; wherein X 22 represents a nitrogen atom which is independently unsubstituted, or mono-substituted with C 1-4 -alkyl or C 3-6 -cycloalkyl; or

-L 9 -HET 1 , wherein HET 1 represents 5- or 6-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl; wherein said HET 1 independently is unsubstituted or mono-, or di-substituted wherein the substituents are independently selected from C 1-4 -alkyl; halogen; cyano; hydroxy; hydroxymethyl; -C 0-2 -alkylene-Cy 91 -COOR O91 wherein R O91 is hydrogen or C 1-4 -alkyl, and wherein Cy 91 represents a C 3-6 -cycloalkylene group; or -C 0-2 -alkylene-COOR O92 wherein R O92 is hydrogen or C 1-4 -alkyl; and

-L 9 - independently represents

-C 0-6 -alkylene-, or —CO-C 0-6 -alkylene-;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein

W represents N, Z represents CH; and R 2 is hydrogen, methyl, methoxy or ethoxy;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 , wherein R 3 represents difluoromethoxy;

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 , wherein the fragment:

represents:

wherein R 1 is hydrogen or fluoro; R 2 is hydrogen, chloro, methyl, ethyl, methoxy or ethoxy; and R3 is -C1 3-alkoxy or C1-3-fluoroalkoxy; or

wherein R 1 is hydrogen; R 2 is halogen, methyl, or methoxy; and R 3 is C 1-3 -fluoroalkoxy;

or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 , wherein the fragment:

represents a ring independently selected from the following groups A) or B):

or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 , wherein Ar 1 represents phenyl;

wherein said phenyl group is substituted with R 4 and R 5 , wherein

R 4 represents n-propyl, isopropyl, or monocyclic C 3-6 -cycloalkyl; and

R 5 represents hydrogen, fluoro, or methyl;

or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 , wherein the fragment:

represents a ring independently selected from the following groups:

or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1 , wherein the group -L—R 6 represents

-L 1 -COOH; and

-L 1 - represents

—CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —, —CH 2 —C(CH 3 ) 2 —CH 2 —, *—CH 2 —CH 2 —C(CH 3 ) 2 —, *—CH 2 —CH 2 —CH 2 —C(CH 3 ) 2 —, *—CO—CH 2 —CH 2 —, *—CO—CH(CH 3 )—CH 2 —, *—CO—CH 2 —C(OH)(CH 3 )—, *—CO—CH 2 —CH 2 —CH 2 —, *—CO—CH 2 —C(CH 3 ) 2 —, *—CO—C(CH 3 ) 2 —CH 2 —, *—SO 2 —CH 2 —, *—SO 2 —CH 2 —CH 2 —, *—SO 2 —CH 2 —CH 2 —CH 2 —, *—SO 2 —CH 2 —C(CH 3 ) 2 —, *—CO—O—CH 2 —, *—CO—O—CH(CH 3 )—, *—CO—O—CH 2 —C(CH 3 ) 2 —, *—CO—NH—C(CH 3 ) 2 —CH 2 —, *—CO—NH—CH 2 —C(CH 3 ) 2 —, *—CO—NH—CH 2 —CH 2 —C(CH 3 ) 2 —, *—SO 2 —NH—CH 2 —; *—CH 2 —CH 2 —CH 2 -cyclopropane-1,1-diyl-, *—CO-cyclopropane-1,2-yl-, *—CO—CH 2 -cyclopropane-1,1-diyl-, *—CO—CH 2 -cyclobutane-1,1-diyl-, *—SO 2 -cyclopropane-1,1-diyl—CH 2 —, *—CO—O-cyclopropane-1,1-diyl-, *—CO—O—CH 2 -cyclopropane-1,1-diyl-;

*—CO—CH 2 —(tetrahydro-2H-pyran-4,4-diyl)-;

*—CO—CH 2 —N(n-butyl)—CH 2 —;

*—SO 2 —CH═CH—, *—CO—C(CH 2 )—CH 2 —; or

*—CO—CF 2 —CH 2 —;

-L 2 -hydroxy; wherein -L 2 - represents

*—CH 2 —CH(OH)—CH 2 —; or

*—CO—CH 2 —NH—CH 2 —CH 2 —, *—CO—CH 2 —NH—CH(CH 3 )—CH 2 —, *—CO—CH 2 —NH—CH 2 —CH(CH 3 )—; or

-L 9 -HET 1 , wherein -L 9 -HET 1 represents

wherein in the above groups the asterisks indicate the bond which is connected to the rest of the molecule;

or a pharmaceutically acceptable salt thereof.

9. A compound, wherein said compound is:

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(2-aminoethyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-cyano-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(3-(1H-tetrazol-5-yl)propyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-hydroxy-3-methylbutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-(1-hydroxycyclopropyl)ethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(2-aminopropyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

3-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoic acid;

1-(2-cyanoethyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

(R)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(oxetan-3-yl)azetidine-3-carboxamide;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,3-dimethylbutanoic acid;

5-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)-1H-pyrrole-2-carboxylic acid;

5-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)furan-2-carboxylic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(4-hydroxy-4-methylpentyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

5-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylpentanoic acid;

1-(3-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propyl)cyclopropane-1-carboxylic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(2-(methylsulfonamido)ethyl)azetidine-3-carboxamide;

(S)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-hydroxy-3-(2-hydroxyacetamido)propyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(cyanomethyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(2-(1H-tetrazol-5-yl)ethyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(4-cyanobutanoyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-acetyl-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(3-sulfamoylpropanoyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(2-(N-methylsulfamoyl)acetyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-((methylsulfonyl)glycyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(N-methyl-N-sulfamoylglycyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(5,5,5-trifluoro-4-oxopentanoyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-hydroxyisoxazole-5-carbonyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-oxo-2,3-dihydroisoxazole-5-carbonyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(2-(2H-1,2,3-triazol-2-yl)acetyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-(3-hydroxy-1H-pyrazol-4-yl)acetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(2-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)acetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(L-alanyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-((2-hydroxyethyl)glycyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-((2-methoxyethyl)glycyl)azetidine-3-carboxamide;

(R)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-((R)-(2-hydroxypropyl)glycyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

(S)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-((S)-(2-hydroxypropyl)glycyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

(R)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-((R)-(1-hydroxypropan-2-yl)glycyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

(S)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-((R)-(1-hydroxypropan-2-yl)glycyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

3-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-oxopropanoic acid;

3-(4-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidin-1-yl)-3-oxopropanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-oxobutanoic acid;

4-(4-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidin-1-yl)-4-oxobutanoic acid;

(S)-4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methyl-4-oxobutanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

1-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)cyclopropane-1-carboxylic acid;

1-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)cyclobutane-1-carboxylic acid;

(R)-4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methyl-4-oxobutanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,3-dimethyl-4-oxobutanoic acid;

3-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)but-3-enoic acid;

(1S,2R)-2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)cyclopropane-1-carboxylic acid;

(1R,2S)-2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)cyclopropane-1-carboxylic acid;

5-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-oxopentanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,3-difluoro-4-oxobutanoic acid;

(S)-4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-hydroxy-2-methyl-4-oxobutanoic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(5,5,5-trifluoro-4-hydroxypentanoyl)azetidine-3-carboxamide;

4-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)tetrahydro-2H-pyran-4-carboxylic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(sulfamoylglycyl)azetidine-3-carboxamide;

1-(N-acetyl-N-hydroxyglycyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

2-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)acetic acid;

3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)propanoic acid;

3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)-2,2-dimethylpropanoic acid;

2-(1-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)cyclopropyl)acetic acid;

4-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)butanoic acid;

(E)-3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)acrylic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-((3-(hydroxyamino)-3-oxopropyl)sulfonyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

2-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)acetic acid;

(R)-2-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)propanoic acid;

1-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)cyclopropane-1-carboxylic acid;

3-((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)-2,2-dimethylpropanoic acid;

1-(((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)methyl)cyclopropane-1-carboxylic acid;

((3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)glycine;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(2-(sulfamoylamino)ethyl)azetidine-3-carboxamide;

3-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxamido)-3-methylbutanoic acid;

3-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxamido)-2,2-dimethylpropanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxamido)-2,2-dimethylbutanoic acid;

6-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid;

6-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid;

2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-5-carboxylic acid;

6-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylic acid;

5-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylic acid;

1-(5-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidin-2-yl)cyclopropane-1-carboxylic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(4-fluoropyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(3-fluoropyridin-4-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(5-fluoropyrimidin-4-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)pyridin-3-yl)-1-(5-fluoropyrimidin-4-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(5-cyanopyridin-2-yl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(5-cyanopyridin-2-yl)-N-(2-(difluoromethoxy)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(5-cyanopyrimidin-2-yl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

1-(5-cyanopyrimidin-2-yl)-N-(2-(difluoromethoxy)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-4-carboxylic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(5-fluoropyrimidin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(2-methylpyrimidin-4-yl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrooxazol-2-yl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(4-hydroxy-oxazol-2-yl)azetidine-3-carboxamide];

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-1-(5-hydroxy-1,2,4-oxadiazol-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-isopropylphenyl)-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)azetidine-3-carboxamide];

3-(2-cyclopentylphenyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)azetidine-3-carboxamide;

3-(2-cyclohexylphenyl)-N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)azetidine-3-carboxamide;

4-(3-(2-cyclobutylphenyl)-3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-(2-cyclopentylphenyl)-3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-(2-cyclohexylphenyl)-3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-propylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

N-(2-(difluoromethoxy)-6-methylpyridin-3-yl)-3-(2-fluoro-6-isopropylphenyl)azetidine-3-carboxamide;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropyl-5-methylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-fluoro-6-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(5-fluoro-2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

N-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)-N-propylglycine;

Methyl N-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)-N-(2-methoxyethyl)glycinate;

N-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)-N-(2-methoxyethyl)glycine;

Methyl (2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)glycinate;

(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)glycine;

N-(2-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)-N-ethylglycine;

N-(5-chloro-3-methoxypyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(5-bromo-3-methoxypyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(5-chloro-3-(difluoromethoxy)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(5-bromo-3-(difluoromethoxy)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(3-(difluoromethoxy)-5-methylpyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(3,5-dimethoxypyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;

N-(5-chloro-3-(difluoromethoxy)pyridin-2-yl)-3-(2-cyclopentylphenyl)azetidine-3-carboxamide;

Methyl 4-(3-((5-chloro-3-(difluoromethoxy)pyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoate;

4-(3-((5-chloro-3-(difluoromethoxy)pyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid;

4-(3-((5-bromo-3-(difluoromethoxy)pyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid;

4-(3-((5-bromo-3-(difluoromethoxy)pyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

Methyl 4-(3-((5-bromo-3-(difluoromethoxy)pyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate;

4-(3-((5-chloro-3-(difluoromethoxy)pyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-((5-chloro-3-methoxypyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-((5-bromo-3-methoxypyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

4-(3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

1-(2-(3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-oxoethyl)cyclobutane-1-carboxylic acid;

Benzyl 3-((3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)propanoate;

3-((3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)propanoic acid;

N 3 -(5-chloro-3-(difluoromethoxy)pyridin-2-yl)-N 1 -cyclopropyl-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide;

N 3 -(5-bromo-3-(difluoromethoxy)pyridin-2-yl)-N 1 -cyclopropyl-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide;

2-methoxy-2-oxoethyl 3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;

2-((3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)acetic acid;

1-((3-((3-(difluoromethoxy)-5-methylpyridin-2-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)cyclopropane-1-carboxylic acid; or

N-(3-(difluoromethoxy)-5-methylpyridin-2-yl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrooxazol-2-yl)azetidine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

11. A method for the prophylaxis or treatment of fibrosis, or dermatological disorders which are proliferative or inflammatory disorders of the skin; comprising administering to a subject in need thereof an effective amount of a compound as defined in claim 1 , or of a pharmaceutically acceptable salt thereof.

12. A compound, wherein said compound is:

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid;

or a pharmaceutically acceptable salt thereof.

13. A compound, wherein said compound is:

4-(3-((2-(difluoromethoxy)-6-methylpyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid;

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound according to claim 9 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising the compound according to claim 12 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising the compound according to claim 13 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

17. A method for the prophylaxis or treatment of fibrosis, or dermatological disorders which are proliferative or inflammatory disorders of the skin; comprising administering to a subject in need thereof an effective amount of the compound as defined in claim 12 , or of a pharmaceutically acceptable salt thereof.

18. A method for the prophylaxis or treatment of fibrosis, or dermatological disorders which are proliferative or inflammatory disorders of the skin; comprising administering to a subject in need thereof an effective amount of the compound as defined in claim 13 , or of a pharmaceutically acceptable salt thereof.

19. A method for the treatment of pulmonary fibrosis or systemic sclerosis;

comprising administering to a subject in need thereof an effective amount of a compound as defined in claim 1 , or of a pharmaceutically acceptable salt thereof.

20. A method for the treatment of pulmonary fibrosis or systemic sclerosis;

comprising administering to a subject in need thereof an effective amount of the compound as defined in claim 12 , or of a pharmaceutically acceptable salt thereof.

21. A method for the treatment of pulmonary fibrosis or systemic sclerosis; comprising administering to a subject in need thereof an effective amount of the compound as defined in claim 13 , or of a pharmaceutically acceptable salt thereof.

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Jun 25, 2026
From: IDORSIA PHARMACEUTICALS LTD
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 076038/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: LESCOP, CYRILLE
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 054682/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: BOLLI, MARTIN; BROTSCHI, CHRISTINE; WILLIAMS, JODI T.
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 054795/0851 →
Priority Claims (1)
WO PCT/EP2018/065016 · Jun 7, 2018 · international
Continuity (1)
Related Publication 20210246116A1 · Aug 12, 2021
References Cited (117)
US 3097209A · Janssen · 1963 [cited by applicant]
US 6734184B1 · Barlaam et al. · 2004 [cited by applicant]
US 7288558B2 · Nakade et al. · 2007 [cited by applicant]
US 7855290B2 · Matsushima et al. · 2010 [cited by applicant]
US 8466115B2 · Curtis et al. · 2013 [cited by applicant]
US 20070078120A1 · Ban et al. · 2007 [cited by applicant]
US 20080207573A1 · Yager et al. · 2008 [cited by applicant]
EP 1364659 · 2003 [cited by applicant]
EP 2481725 · 2012 [cited by applicant]
JP 2008110971 · 2008 [cited by applicant]
WO WO1996011940 · 1996 [cited by applicant]
WO WO2000012478 · 2000 [cited by applicant]
WO WO2001032173 · 2001 [cited by applicant]
WO WO2001077077 · 2001 [cited by applicant]
WO WO2002062389 · 2002 [cited by applicant]
WO WO2003088908 · 2003 [cited by applicant]
WO WO2004085385 · 2004 [cited by applicant]
WO WO2004110350 · 2004 [cited by applicant]
WO WO2005023761 · 2005 [cited by applicant]
WO WO2005037269 · 2005 [cited by applicant]
WO WO2005049605 · 2005 [cited by applicant]
WO WO2006073967 · 2006 [cited by applicant]
WO WO2006091862 · 2006 [cited by applicant]
WO WO2007058990 · 2007 [cited by applicant]
WO WO2007146712 · 2007 [cited by applicant]
WO WO2008115281 · 2008 [cited by applicant]
WO WO2009051715 · 2009 [cited by applicant]
WO WO2009131940A1 · 2009 [cited by applicant]
WO WO2009135590 · 2009 [cited by applicant]
WO WO2010023181 · 2010 [cited by applicant]
WO WO2011037192 · 2011 [cited by applicant]
WO WO2012017359 · 2012 [cited by applicant]
WO WO2012055995 · 2012 [cited by applicant]
WO WO2012078805 · 2012 [cited by applicant]
WO WO2012082817 · 2012 [cited by applicant]
WO WO2012120399 · 2012 [cited by applicant]
WO WO2013096771 · 2013 [cited by applicant]
WO WO2014079805 · 2014 [cited by applicant]
WO WO2017177004 · 2017 [cited by applicant]
WO WO2020254408A1 · 2020 [cited by applicant]
WO WO2021110805A1 · 2021 [cited by applicant]
Datta. British Journal of Pharmacology, 2011, 163, 141-172 (Year: 2011). [cited by examiner]
Cuzick. The Lancet, 2014, 15, e484-e492 (Year: 2014). [cited by examiner]
Gonzalez-Gil. Medicinal Chemistry Communications, 2015, 6, 13-23 (Year: 2015). [cited by examiner]
Teo. Biochemical Journal, 2014, 463, 157-165 (Year: 2014). [cited by examiner]
Azoury. Surgical Clinics of North America, 2014, 94, 945-962 (Year: 2014). [cited by examiner]
Ulrich. British Journal of Dermatology, 2009, 161, 78-84 (Year: 2009). [cited by examiner]
Simpson. Journal of the American Academy of Dermatology, 2010, 587-593 (Year: 2010). [cited by examiner]
Wilson. Mucosa/Immunology, 2009, 2(2), 103-121 (Year: 2009). [cited by examiner]
Davenport. Organic Process Research & Development, 2024, 28, 577-587 (Year: 2024). [cited by examiner]
U.S. Appl. No. 17/620,520, filed Dec. 17, 2021 (371(c) Date), Bolli et al. [cited by applicant]
Sakamoto, K. et al., “Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation,” The Journal of Pharmacology and Experimental Therapeutics, 2018, … [cited by applicant]
U.S. Appl. No. 17/782,530, filed Jun. 3, 2022 (371(c) Date), Birker et al. [cited by applicant]
Ahmed et al., “Expression of autotaxin and acylglycerol kinase in proliferative vitreoretinal epiretinal membranes,” Acta Ophthalmol, vol. 90, pp. e84-e89, (2012). [cited by applicant]
An et al., “Molecular Cloning of the Human Edg2 Protein and Its Identification as a Functional Cellular Receptor for Lysophosphatidic Acid,” Biochem. Biophys. Res. Comm., vol. 231, pp. 619-622, (1997). [cited by applicant]
Baker et al., “Direct Quantitative Analysis of Lysophosphatidic Acid Molecular Species by Stable Isotope Dilution Electrospray Ionization Liquid Chromatography—Mass Spectrometry,” Biochem., vol. 292, pp. 287-295, (2001). [cited by applicant]
Boucharaba et al., “Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer,” J. Clin. Invest., vol. 114, No. 12, pp. 1714-1725, (2004); https://doi.org/10.1172/JCI… [cited by applicant]
Boucharaba et al., “The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases,” Proc. Natl. Acad. Sci., vol. 103, No. 25, pp. 9643-9648, (2006). [cited by applicant]
Bremner et al., “The Synthesis of Thienopyridines from ortho-Halogenated Pyridine Derivatives,” Synthesis, vol. 6, pp. 528-530, (1992). [cited by applicant]
Brindley, “Lipid Phosphate Phosphatases and Related Proteins: Signaling Functions in Development, Cell Division, and Cancer,” J. Cell Biochem., vol. 92, pp. 900-912, (2004). [cited by applicant]
Castelino et al., “Amelioration of Dermal Fibrosis by Genetic Deletion or Pharmacologic Antagonism of Lysophosphatidic Acid Receptor 1 in a Mouse Model of Scleroderma,” Arthritis Rheum., vol. 63, No. 5, pp. 1405-1415, (… [cited by applicant]
Choi et al., “LPA Receptors: Subtypes and Biological Actions,” Pharmacol. Toxicol., vol. 50, pp. 157-186, (2010). [cited by applicant]
Choi et al., “Lysophospholipids and their receptors in the central nervous system,” Biochim. Biophys. Acta, vol. 1831, pp. 20-32, (2013). [cited by applicant]
Chun, J., Hla, T., Spiegel, S., Moolenaar, W., Editors, Lysophospholipid Receptors: Signaling and Biochemistry, 2013, Wiley; ISBN: 978-0-470-56905-4. [cited by applicant]
Dollé et al., “Studies towards 4-C-Alkylation of Pyridin-2(1H)-one Derivatives,” Tetrahedron, vol. 53, No. 37, pp. 12505-12524, (1997). [cited by applicant]
D'Souza et al., “Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance,” Nutrients, vol. 10, No. 399, pp. 1-20, (2018). [cited by applicant]
Fujiwara et al., “Identification of Residues Responsible for Ligand Recognition and Regioisomeric Selectivity of Lysophosphatidic Acid Receptors Expressed in Mammalian Cells,” J. Biol. Chem., vol. 280, No. 41, pp. 35038… [cited by applicant]
Georas et al., “Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge,” Clin. Exp. Allergy, vol. 37, No. 3, pp. 311-322, (2007). [cited by applicant]
Gill et al., “Pigments of Fungi. LIX*† Synthesis of (1S,3S)- and (1R,3R)-Austrocortilutein and (1S,3S)-Austrocortirubin from Citramalic Acid,” Aust. J. Chem., vol. 53, pp. 245-256, (2000). [cited by applicant]
Goetzl et al., “Lysophospholipid Growth Factors and Their G Protein-Coupled Receptors in Immunity, Coronary Artery Disease, and Cancer,” Scientific World J., vol. 2, pp. 324-338, (2002). [cited by applicant]
Guo et al., “Mitogenic Signaling in Androgen Sensitive and Insensitive Prostate Cancer Cell Lines,” J. Urology, vol. 163, pp. 1027-1032, (2000). [cited by applicant]
“Handbook of Pharmaceutical Salts. Properties, Selection and Use,” P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008. [cited by applicant]
Hecht et al., “Ventricular Zone Gene-1 (vzg-1) Encodes a Lysophosphatidic Acid Receptor Expressed in Neurogenic Regions of the Developing Cerebral Cortex,” J. Cell. Biol., vol. 135, pp. 1071-1083, (1996). [cited by applicant]
Inoue et al., “Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling,” Nat. Med., vol. 10, No. 7, pp. 712-718, (2004). [cited by applicant]
Kerins et al., “Generation of Substituted Styrenes via Suzuki Cross-Coupling of Aryl Halides with 2,4,6-Trivinylcyclotriboroxane,” J. Org. Chem., vol. 67, pp. 4968-4971, (2002). [cited by applicant]
Kocienski, P. J., Protecting Groups, Thieme Stuttgart, 1994. [cited by applicant]
Komachi et al., “Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastisi in vivo,” Cancer Sci., vol. 103, No. 6, pp. 1099-1104, (2012). [cited by applicant]
Kropp et al., “Characterization of Cultured Bladder Smooth Muscle Cells: Assessment of in Vitro Contractility,” J. Urology, vol. 162, pp. 1779-1784, (1999). [cited by applicant]
Kuner, “Central mechanisms of pathological pain,” Nat. Med., vol. 16, No. 11, pp. 1258-1266, (2010). [cited by applicant]
Li et al., “Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice,” Kidney International, vol. 91, No. 6, pp. 1362-1372, (2017). [cited by applicant]
Lin et al., “Lysophosphatidic acid receptor 1 is important for intestinal epithelial barrier function and susceptibility to colitis,” Am. J. Pathol., vol. 188, No. 2, pp. 353-366, (2018). [cited by applicant]
Liu et al., “Highly controlling selectivity of copper(I)-catalyzed azide/alkyne cycloaddition (CuAAC) between sulfonyl azids and normal alkynes or propynoates,” Tetrahedron, vol. 67, pp. 6294-6299, (2011). [cited by applicant]
Matsushita et al., “Palladium-Catalyzed Reactions of Allylic Electrophiles with Organometallic Reagents. A Regioselective 1,4-Elimination and a Regio- and Stereoselective Reduction of Allylic Derivatives,” Org. Chem., v… [cited by applicant]
Möbus et al., “Hydrogenation of Aromatic Nitrogroups with Precious Metal Powder Catalysts: Influence of Modifier on Selectivity and Activity,” Top. Catal., vol. 53, pp. 1126-1131, (2010). [cited by applicant]
Montalbetti et al., “Amide bond formation and peptide coupling,” Tetrahedron, vol. 46, pp. 10827-10852, (2005). [cited by applicant]
Moolenaar et al., “The ins and outs of lysophosphatidic acid signaling,” BioEssays, vol. 26, pp. 870-881, (2004). [cited by applicant]
Nagai et al., “Autotaxin and lysophosphatidic acid [cited by applicant]
Onorato et al., “Challenges in accurate quantitation of lysophosphatidic acids in human biofluids,” J. Lipid Res., vol. 55, pp. 1984-1796, (2014). [cited by applicant]
“Pharmaceutical Salts and Co-crystals,” John Wouters and Luc Quéré (Eds.), RSC Publishing, 2012. [cited by applicant]
Pradère et al., “LPA [cited by applicant]
“Protective Groups in Organic Synthesis,” T.W. Greene, P.G.M. Wuts, Wiley-Interscience, 1999. [cited by applicant]
Rancoule et al., “Lysophosphatidic acid-1-receptor targeting agents for fibrosis,” Expert. Opin. Inv. Drug, vol. 20, No. 85, pp. 657-667, (2011). [cited by applicant]
Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]. [cited by applicant]
Rockey et al., “Fibrosis—A Common Pathway to Organ Injury and Failure,” New Engl. J. Med., vol. 372, pp. 1138-1149, (2015). [cited by applicant]
Simon et al., “Lysophosphatidic Acid Inhibits Adipocyte Differentiation via Lysophosphatidic Acid 1 Receptor-dependent Down-regulation of Peroxisome Proliferator-activated Receptor [cited by applicant]
Sperry et al., “A Safe and Practical Procedure for the Difluoromethylation of Methyl 4-Hydroxy-3-iodobenzoate,” Org. Process Res. Dev., vol. 15, pp. 721-725, (2011). [cited by applicant]
Stepan et al., “Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active [cited by applicant]
Stoddard et al., “Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling,” Biomol. Ther., vol. 23, No. 1, pp. 1-11, (2015). [cited by applicant]
Tager et al., “The lysophosphatidic acid receptor LPA [cited by applicant]
Thomoson et al., “Use of fluoroform as a source of difluorocarbene in the synthesis of N-CF [cited by applicant]
Valeur et al., “Amide bond formation: beyond the myth of coupling reagents,” Chem. Soc. Rev., vol. 389, pp. 606-631, (2009). [cited by applicant]
Van Leeuwen, “Lysophosphatidic acid: mitogen and motility factor,” Biochem. Soc. Trans., vol. 31, pp. 1209-1212, (2003). [cited by applicant]
Watanabe et al., “Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C,” J. Clin. Gastroenterol., vol. 41, No. 6, pp. 616-623, (2007). [cited by applicant]
Watanabe et al., “Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity,” Life Sciences, vol. 81, pp. 1009-1015, (2007). [cited by applicant]
Yamada et al., “Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA [cited by applicant]
Yang et al., “The Role of Lysophosphatidic Acid Receptor (LPA [cited by applicant]
Zeng et al., “Gene expression Profiles of Lysophosphatidic Acid-Related Molecules in the Prostate: Relevance to Prostate Cancer and Benign Hyperplasia,” The Prostate, vol. 69, pp. 283-292, (2009). [cited by applicant]
Zhao et al., “Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling,” Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Of Lipids, vol. 1831, pp. 86-92, (2013). [cited by applicant]
Allanore, Y. et al., “Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis,” Arthritis & Rheumatology, 2018, 70 (10), 1634-1643. [cited by applicant]
Bristol Myers Squibb, “Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study,” dated Sep. 9, 2023, 3 pages, retrieved on A… [cited by applicant]
ClinicalTrials.gov, “Proof of Biological Activity of SAR100842 in Systemic Sclerosis,” ClinicalTrials.gov ID: NCT01651143, Document states last update posted: Mar. 25, 2016, 9 pages, retrieved on Apr. 19, 2024, from: ht… [cited by applicant]
ClinicalTrials.gov, “A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis,” ClinicalTrials.gov ID: NCT04781543, Documen… [cited by applicant]
ClinicalTrials.gov, “An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc),” ClinicalTrials.gov ID: NCT05626751, Document states last u… [cited by applicant]
Corte, T. et al., “Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA [cited by applicant]
Ledein, L. et al., “Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse,” British Journal of Pharmacology, 2020, 177,… [cited by applicant]
U.S. Appl. No. 17/620,520, Preliminary Amendment filed Dec. 17, 2021, 25 pages. [cited by applicant]
U.S. Appl. No. 17/782,530, Preliminary Amendment filed Jun. 3, 2022, 11 pages. [cited by applicant]
Cited By (2)
US 12,479,820 US 12,539,294